JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 3,653 articles

Articles by James Calloway

Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Earnings

Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update

Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.

CAPR
Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling
Earnings

Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling

Unusual Machines shares climbed 7% Monday following preliminary results showing 2025 revenue more than doubled to $11.2 million and cash reserves topped $103 million. The drone components maker also reported a widened quarterly operating loss.

UMAC
W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief
Earnings

W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief

W&T Offshore disclosed a deeper net loss for 2025, with revenue declining to $501.5 million. The company highlighted reduced net debt and potential regulatory relief from proposed offshore financial assurance rules.

WTI TALO MUR USO XLE
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Regulation

Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

RVPH BMY VNDA XLV
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
Regulation

uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute

uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.

QURE
3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts
Earnings

3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts

3D Systems reported Q4 revenue of $106.3M, exceeding its forecast, though full-year sales fell 12%. The company anticipates a revenue decline and continued losses for the current quarter.

DDD
Micron Shares Retreat Ahead of Key Index Inclusion and Earnings Report
Earnings

Micron Shares Retreat Ahead of Key Index Inclusion and Earnings Report

Micron Technology shares declined roughly 6.7% before Monday's opening bell, pressured by broader market weakness and anticipation surrounding upcoming earnings and index rebalancing.

MU AIG MET TGT LRCX AMAT
Palantir Faces Pentagon AI Ban Fallout as Defense Tech Reliance Questioned
Regulation

Palantir Faces Pentagon AI Ban Fallout as Defense Tech Reliance Questioned

Palantir Technologies confronts new risks as the U.S. Pentagon designates AI supplier Anthropic a supply-chain threat, raising concerns over its defense software dependencies. Broader market jitters add to the pressure.

PLTR MSFT USO XLE XLK
Broadcom's AI Surge Faces Market Test After Strong Outlook
Earnings

Broadcom's AI Surge Faces Market Test After Strong Outlook

Broadcom's AI revenue jumped 106% to $8.4 billion last quarter, with a new $10.7 billion target set for the current period. The chipmaker's stock will be tested as investors digest its aggressive growth forecast amid broader market declines.

AVGO MRVL NVDA GOOG META
Micron Stock Slumps Ahead of Key Earnings, AI Demand in Focus
Earnings

Micron Stock Slumps Ahead of Key Earnings, AI Demand in Focus

Micron Technology shares dropped 6.7% on Friday, closing at $370.30, as investors look ahead to the company's March 18 earnings call for updates on AI-driven memory demand and competitive pressures.

MU NVDA MRVL AVGO SSNLF FXI XLK
Mesoblast Surges on Ryoncil Sales, Sets $120M Revenue Target
Earnings

Mesoblast Surges on Ryoncil Sales, Sets $120M Revenue Target

Mesoblast Limited's stock climbed 3% in early U.S. trading following strong first-half results fueled by its newly launched cell therapy Ryoncil. The company has established a fiscal 2026 revenue target of $110-120 million for the product.

Sea Stock Retreats as Shopee's Slower Growth Outlook Raises Spending Concerns
Earnings

Sea Stock Retreats as Shopee's Slower Growth Outlook Raises Spending Concerns

Sea Ltd's stock gave back some of its prior-day gains after the company projected slower gross merchandise volume growth for its Shopee unit in 2026 alongside a significant quarterly cost increase, prompting investor reassessment of its spending plans.

SE